BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

KMR Group Release: Report on Enrollment Metrics Shows Untapped Potential


2/16/2012 2:26:43 PM

CHICAGO, Illinois, February 16, 2012 - The Enrollment Metrix Forum recently completed an analysis of how the biopharmaceutical industry is using performance metrics in the most time consuming and expensive portion of the clinical trials process -- enrollment. The analysis was based on data of 11 companies: Amgen, AZ, Bayer, BMS, J&J, Lilly, Merck Research Laboratories, Pfizer, Roche, Shire, UCB.

Although a wide range of enrollment metrics are tracked and reported internally by the companies -- at both the trial and investigator site levels -- it was notable that most companies do not employ these to evaluate their own performance. They are rather used more to set timelines and expectations for future studies.

Another interesting finding was that most companies have not adopted a centralized approach to selecting sites, but instead rely on more decentralized information and decision-making by affiliates at the region or country level or, in some cases, on individual project teams or study managers. Some companies employ a hybrid approach, where the selection is decentralized but there is a central group that either approves or assists in this selection.

Such centralized groups often tap into external databases with information on sites. A key area where there has been recent progress for selecting sites has been the ability to access actual performance data of specific sites (through Site Scorecard), not just contact information or the expertise of the site but how well it has performed when conducting recent trials: e.g., patients randomized per month by the site, randomization cycle time at the site.

"It was illuminating to see the variance in the Industry, not so much in what metrics are tracked but how they are being used," according to Linda Martin of KMR Group, which facilitated the assessment for the Enrollment Metrix Forum. She continued: "This comparison across the companies revealed that there are important ways in which the data that is generally available can be more effectively used. While the Industry has made considerable strides in the last 5 years, at some companies the potential for improvement is still substantial, and can help lead to more effective management of their trials. This is particularly true when evaluating and managing sites."

For further information contact:

Linda Martin, Principal Tel: +1 (312) 795-0400 Email: lmartin@kmrgroup.com

About KMR

Founded in 1991, KMR is a leader in benchmarking, analytics and performance management in the biopharmaceutical R&D industry. KMR’s clinical platform contains the industry's most reliable source for trial performance, recruitment and site metrics data. Clients use KMR’s Enrollment and Site Metrix tools to define recruitment strategies, shape enrollment plans and forecast recruitment. Our newest tool, Site Scorecard, provides companies with access to performance data and industry benchmarks for named sites. For more information about these reports or for a demonstration of any of KMR’s tools, please contact KMR or visit our website at https://www.kmrgroup.com.

KMR Group

150 North Wacker Drive, Suite 1070 • Chicago, Illinois 60606 USA

1-312-795-0400 • Fax 1-312-795-0491 www.kmrgroup.com Copyright © KMR Group 2012 All rights reserved.



Read at BioSpace.com

KMR Group
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES